241 related articles for article (PubMed ID: 11263528)
21. [The adenovirus-mediated HSV-TK/GCV suicide gene system in the treatment of tongue carcinoma cell line].
Huang H; Wang A
Zhonghua Kou Qiang Yi Xue Za Zhi; 2001 Nov; 36(6):457-60. PubMed ID: 11930726
[TBL] [Abstract][Full Text] [Related]
22. Similar efficiency of DNA-liposome complexes and retrovirus-producing cells for HSV-tk suicide gene therapy of peritoneal carcinomatosis.
Princen F; Lechanteur C; Lopez M; Gielen J; Bours V; Merville MP
J Drug Target; 2000; 8(2):79-89. PubMed ID: 10852340
[TBL] [Abstract][Full Text] [Related]
23. Use of protamine to augment adenovirus-mediated cancer gene therapy.
Lanuti M; Kouri CE; Force S; Chang M; Amin K; Xu K; Blair I; Kaiser L; Albelda S
Gene Ther; 1999 Sep; 6(9):1600-10. PubMed ID: 10490770
[TBL] [Abstract][Full Text] [Related]
24. [Effects of retrovirus-mediated HSV-tk/GCV on human hepatocellular carcinoma].
Zhao Y; Zhang X; Hui H
Zhonghua Gan Zang Bing Za Zhi; 1999 Jun; 7(2):113-5. PubMed ID: 10488424
[TBL] [Abstract][Full Text] [Related]
25. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
[TBL] [Abstract][Full Text] [Related]
26. Osteosarcoma and chondrosarcoma as targets for virus vectors and herpes simplex virus thymidine kinase/ganciclovir gene therapy.
Ketola A; Määttä AM; Pasanen T; Tulimäki K; Wahlfors J
Int J Mol Med; 2004 May; 13(5):705-10. PubMed ID: 15067374
[TBL] [Abstract][Full Text] [Related]
27. [Effects of adenovirus-mediated HSV-tk/GCV system on lens epithelium].
Wang B; Weng J
Zhonghua Yan Ke Za Zhi; 2002 Oct; 38(10):618-22. PubMed ID: 12487913
[TBL] [Abstract][Full Text] [Related]
28. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression.
Kaneko S; Hallenbeck P; Kotani T; Nakabayashi H; McGarrity G; Tamaoki T; Anderson WF; Chiang YL
Cancer Res; 1995 Nov; 55(22):5283-7. PubMed ID: 7585589
[TBL] [Abstract][Full Text] [Related]
29. HSV-tk gene therapy for human renal cell carcinoma in nude mice.
Pulkkanen KJ; Parkkinen JJ; Laukkanen JM; Kettunen MI; Tyynela K; Kauppinen RA; Ala-Opas MY; Yla-Herttuala S
Cancer Gene Ther; 2001 Jul; 8(7):529-36. PubMed ID: 11498775
[TBL] [Abstract][Full Text] [Related]
30. The role of a HSV thymidine kinase stimulating substance, scopadulciol, in improving the efficacy of cancer gene therapy.
Hayashi K; Lee JB; Maitani Y; Toyooka N; Nemoto H; Hayashi T
J Gene Med; 2006 Aug; 8(8):1056-67. PubMed ID: 16779868
[TBL] [Abstract][Full Text] [Related]
31. Imaging adenoviral-mediated herpes virus thymidine kinase gene transfer and expression in vivo.
Tjuvajev JG; Chen SH; Joshi A; Joshi R; Guo ZS; Balatoni J; Ballon D; Koutcher J; Finn R; Woo SL; Blasberg RG
Cancer Res; 1999 Oct; 59(20):5186-93. PubMed ID: 10537296
[TBL] [Abstract][Full Text] [Related]
32. Enhanced anti-tumor effects of herpes simplex virus thymidine kinase/ganciclovir system by codelivering monocyte chemoattractant protein-1 in hepatocellular carcinoma.
Sakai Y; Kaneko S; Nakamoto Y; Kagaya T; Mukaida N; Kobayashi K
Cancer Gene Ther; 2001 Oct; 8(10):695-704. PubMed ID: 11687892
[TBL] [Abstract][Full Text] [Related]
33. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer.
Hall SJ; Canfield SE; Yan Y; Hassen W; Selleck WA; Chen SH
Gene Ther; 2002 Apr; 9(8):511-7. PubMed ID: 11948376
[TBL] [Abstract][Full Text] [Related]
34. Differential cytotoxicity and bystander effect of the rabbit cytochrome P450 4B1 enzyme gene by two different prodrugs: implications for pharmacogene therapy.
Frank S; Steffens S; Fischer U; Tlolko A; Rainov NG; Kramm CM
Cancer Gene Ther; 2002 Feb; 9(2):178-88. PubMed ID: 11857036
[TBL] [Abstract][Full Text] [Related]
35. Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene.
Esandi MC; van Someren GD; Vincent AJ; van Bekkum DW; Valerio D; Bout A; Noteboom JL
Gene Ther; 1997 Apr; 4(4):280-7. PubMed ID: 9176512
[TBL] [Abstract][Full Text] [Related]
36. Characterization of HIV-1 TAT peptide as an enhancer of HSV-TK/GCV cancer gene therapy.
Rautsi O; Lehmusvaara S; Ketola A; Määttä AM; Wahlfors J; Pellinen R
Cancer Gene Ther; 2008 May; 15(5):303-14. PubMed ID: 18309353
[TBL] [Abstract][Full Text] [Related]
37. Treatment of rat experimental brain tumors by herpes simplex virus thymidine kinase gene-transduced allogeneic tumor cells and ganciclovir.
Namba H; Tagawa M; Miyagawa T; Iwadate Y; Sakiyama S
Cancer Gene Ther; 2000 Jun; 7(6):947-53. PubMed ID: 10880027
[TBL] [Abstract][Full Text] [Related]
38. Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors.
Brand K; Arnold W; Bartels T; Lieber A; Kay MA; Strauss M; Dörken B
Cancer Gene Ther; 1997; 4(1):9-16. PubMed ID: 9012446
[TBL] [Abstract][Full Text] [Related]
39. TK-GFP fusion gene virus vectors as tools for studying the features of HSV-TK/ganciclovir cancer gene therapy in vivo.
Pasanen T; Hakkarainen T; Timonen P; Parkkinen J; Tenhunen A; Loimas S; Wahlfors J
Int J Mol Med; 2003 Oct; 12(4):525-31. PubMed ID: 12964030
[TBL] [Abstract][Full Text] [Related]
40. Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration.
van der Eb MM; Cramer SJ; Vergouwe Y; Schagen FH; van Krieken JH; van der Eb AJ; Borel Rinkes IH; van de Velde CJ; Hoeben RC
Gene Ther; 1998 Apr; 5(4):451-8. PubMed ID: 9614568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
